Efficace, Fabio
Breccia, Massimo
Avvisati, Giuseppe
Cottone, Francesco
Intermesoli, Tamara
Borlenghi, Erika
Carluccio, Paola
Rodeghiero, Francesco
Fabbiano, Francesco
Luppi, Mario
Romani, Claudio
Sborgia, Marco
D’Ardia, Stefano
Nobile, Francesco
Cantore, Nicola
Crugnola, Monica
Nadali, Gianpaolo
Vignetti, Marco
Amadori, Sergio
Lo Coco, Francesco
Funding for this research was provided by:
Funder: AIRC (Associazione Italiana per la Ricerca sul Cancro) Grant Reference Number: IG15467
Article History
Received: 8 August 2018
Revised: 11 October 2018
Accepted: 24 October 2018
First Online: 20 December 2018
Compliance with ethical standards
:
: FE: Consultancy (Seattle Genetics, Bristol-Myers Squibb, TEVA, Amgen, Orsenix, Incyte); Research funding (Lundbeck, TEVA and Amgen). GA: Honoraria (Teva, Takeda, Roche, Amgen, Jansen). MB: Honoraria for speaking (Novartis, Incyte, Pfizer, BMS). FLC: Consultancy (Orsenix and TEVA); Speakers Bureau (Novartis). The remaining authors declare that they have no conflict of interest.
: The human investigations were performed after approval by a local Human Investigations Committee and in accordance with an assurance filed with and approved by the Department of Health and Human Services, where appropriate.